Clinical aspect of Doxil

Drug Delivery System

Volumn 24, Issue 1, 2009, Pages 35-37

  Fujiwara, Keiichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Doxil; Liposomal doxorubicin; Ovarian cancer; Polyethylene glycol; Stealth

Indexed keywords

DOXORUBICIN;

ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TISSUE LEVEL; FEMALE; HAIR LOSS; HUMAN; OVARY CANCER;

EID: 77953460826     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.24.35     Document Type: Article

References (8)

1. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E et al.: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449, 2004.
2. Bookman MA, Greer BE, Ozols RF: Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOGO 182-ICON5. lnt J Gynecol Cancer 13: 735-740, 2003.
3. Bookman MA: GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Am Soc Clin Oncol, 2006.
4. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME et al.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322, 2001.
5. Gordon AN, Tonda M, Sun S, Rackoff W: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8, 2004.
6. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN et al.: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007.
7. Ferrandina G. Ludovisi M, Lorusso D, Pignata S, Breda E et al.: Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26: 890-896, 2008.
8. Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M et al.: Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol 38: 777-785, 2008.